Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Nov 23, 2006
app pub date -
Mar 21, 2003
filing date -
Mar 22, 2002
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-4 (alpha and beta) and TREM-5 are disclosed. TREM-4 is a transmembrane glycoprotein expressed selectively in the endothelium of capillaries, in the heart and in the testis. Use of TREM-4 in treatment and diagnosis of various inflammatory diseases and heart diseases and male infertility are also provided. TREM-5 is also a transmembrane glycoprotein expressed selectively in bone marrow-derived population of leukocytes, in particular dendritic cells, and may be upregulated in certain conditions, such as cell activation, inflammation or aberrant dendritic cell function. Blockade of TREM-5 with monoclonal antibodies or soluble TREM-5-HuIgG fusion protein may reduce or block skin diseases or dendritic cell associated disorders.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully